England

One Heritage Group plc: Posting of Accounts and Notice of AGM

Retrieved on: 
Tuesday, November 7, 2023
LSE, Gracechurch Street, Account, Truth or Dare: 6th Floor Rear Flat, Annual report, England, AGM, Heritage, Music, Nightclub, Cryptocurrency

One Heritage Group PLC (LSE: OHG), the UK-based residential developer, development manager and property manager focused on the North of England, is pleased to announce that that its Annual Report and Accounts for the year ended 30 June 2023 and Notice of AGM has been posted to shareholders today and is available in full to download from the Company's website (www.oneheritageplc.com).

Key Points: 
  • One Heritage Group PLC (LSE: OHG), the UK-based residential developer, development manager and property manager focused on the North of England, is pleased to announce that that its Annual Report and Accounts for the year ended 30 June 2023 and Notice of AGM has been posted to shareholders today and is available in full to download from the Company's website (www.oneheritageplc.com).
  • The AGM will be held at the offices of Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch Street, London, EC3V 0HR on Thursday 30th November 2023 at 10.00am.

Shareholders of Abcam Approve Proposed Acquisition by Danaher

Retrieved on: 
Monday, November 6, 2023
Research, Finance, Genetics, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Danaher, Youth justice in England and Wales, NYSE, High court, Court, Mass meeting, Acquisition, Transaction, Resolution, Extraordinary general meeting, Proxy, Danaher Corporation, DHR, England, Scheme, Management, Security (finance), Cryptocurrency, Abcam

Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, which entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE: DHR) (‘Danaher’), today announced that its shareholders have approved the proposal for Danaher to acquire all of the outstanding shares of Abcam for $24.00 per share in cash (the ‘Transaction’).

Key Points: 
  • Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, which entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE: DHR) (‘Danaher’), today announced that its shareholders have approved the proposal for Danaher to acquire all of the outstanding shares of Abcam for $24.00 per share in cash (the ‘Transaction’).
  • “With this approval, we are focused on moving swiftly toward transaction close and ensuring a successful transition to deliver maximum value to our shareholders, employees, and customers.”
    “We are thrilled shareholders have overwhelmingly approved the Transaction.
  • This outcome has arrived at the right time for Abcam to embark on the next chapter in its story within the Danaher family,” said Alan Hirzel, Chief Executive Officer of Abcam.
  • The Resolution was therefore passed by the requisite majority of Abcam Shareholders.

Metabolon and Genomics England Announce Partnership to Characterize Hundreds of Rare Diseases and Advance Rare Disease Diagnosis

Retrieved on: 
Wednesday, October 25, 2023
Science, Genomics, Rare disease, Biomarker, Life, Mortality, Data, Research, Quality of life, NHS, Medicine, Partnership, England, NHS England, Metabolomics, Cancer, Patient, Diagnosis, Genomics England, 100,000 Genomes Project, Pharmaceutical industry, Metabolon

MORRISVILLE, N.C., and LONDON, Oct. 25, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, and Genomics England, a UK government-funded organization holding one of the world's largest rare disease datasets, today announce a collaboration to further characterize hundreds of rare diseases to advance the field of rare disease diagnosis. 

Key Points: 
  • Rare diseases are incredibly difficult to analyze and can often take years to obtain a definitive diagnosis, if at all.
  • Metabolon's proprietary precision medicine platform and tools have demonstrated clinical utility for diagnosis, treatment guidance, and monitoring of individuals suffering from rare diseases.
  • It is hoped this research collaboration between Metabolon and Genomics England will enable the rapid discovery of novel biomarkers for known rare diseases and uncover disease-causing pathways for many unknown rare diseases.
  • "We are thrilled to partner with Genomics England to improve the diagnosis of patients with rare disease."

Metabolon and Genomics England Announce Partnership to Characterize Hundreds of Rare Diseases and Advance Rare Disease Diagnosis

Retrieved on: 
Wednesday, October 25, 2023
Science, Genomics, Rare disease, Biomarker, Life, Mortality, Data, Research, Quality of life, NHS, Medicine, Partnership, England, NHS England, Metabolomics, Cancer, Patient, Diagnosis, Genomics England, 100,000 Genomes Project, Pharmaceutical industry, Metabolon

MORRISVILLE, N.C., and LONDON, Oct. 25, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, and Genomics England, a UK government-funded organization holding one of the world's largest rare disease datasets, today announce a collaboration to further characterize hundreds of rare diseases to advance the field of rare disease diagnosis. 

Key Points: 
  • Rare diseases are incredibly difficult to analyze and can often take years to obtain a definitive diagnosis, if at all.
  • Metabolon's proprietary precision medicine platform and tools have demonstrated clinical utility for diagnosis, treatment guidance, and monitoring of individuals suffering from rare diseases.
  • It is hoped this research collaboration between Metabolon and Genomics England will enable the rapid discovery of novel biomarkers for known rare diseases and uncover disease-causing pathways for many unknown rare diseases.
  • "We are thrilled to partner with Genomics England to improve the diagnosis of patients with rare disease."

eMed Healthcare UK promises continuity and expansion following successful acquisition of Babylon - marking a new era for digital-first primary care in the UK

Retrieved on: 
Thursday, October 19, 2023
Digital, Grady EMS, Star, Babylon Health, Health care, Health, American Medical Association, Psychiatry, EMS Healthcare, Acquisition, Digital technology, Care Quality Commission, NHS, Public sector, England, NHS England, Eye, Department of Health and Social Care, NHS Improvement, African, Patient, GP, Health insurance, Video game, Pharmaceutical industry, Nursing, Limited

LONDON, Oct. 19, 2023 /PRNewswire/ -- eMed Healthcare UK, Limited (an operating subsidiary of US digital healthcare company eMed) has acquired Babylon Healthcare Services Limited and certain assets belonging to Babylon Group Holdings Limited and Babylon Partners Limited ("Babylon"). eMed Healthcare UK will continue to provide Babylon's digital-first 24/7 primary care and expand services through eMed's remote chronic care management starting with a clinician-led weight management programme.

Key Points: 
  • LONDON, Oct. 19, 2023 /PRNewswire/ -- eMed Healthcare UK, Limited (an operating subsidiary of US digital healthcare company eMed) has acquired Babylon Healthcare Services Limited and certain assets belonging to Babylon Group Holdings Limited and Babylon Partners Limited ("Babylon").
  • eMed Healthcare UK will continue to provide Babylon's digital-first 24/7 primary care and expand services through eMed's remote chronic care management starting with a clinician-led weight management programme.
  • She added: "Our focus for eMed Healthcare UK will be clinical excellence, high quality care, customer service and redefining chronic care management.
  • eMed Healthcare UK aims to be one of the leading digital-first primary care services in the UK, providing high quality, accessible care for all.

RealWear Offers Students Bird’s-Eye View of Orthopaedic Surgical Procedures in Operating Theatres at North Tees and Hartlepool NHS Foundation Trust

Retrieved on: 
Wednesday, October 11, 2023
Hardware, Surgery, Health, Hospitals, Technology, University, Education, Training, England, Multimedia, North Tees and Hartlepool NHS Foundation Trust, Microsoft, Teaching, County Durham, Health care, Student, GameChanger, Trauma, Workforce, Trust, Environment, Nursing, Growth, NHS, Surgeon, Learning, Emergency, NHS England, Hospital, University Hospital of North Tees

The deployment enables the Department to vastly increase the number of students that can safely experience orthopaedic operating theatre procedures in real-time from the surgeon’s point of view, while optimising the quality of the students’ learning.

Key Points: 
  • The deployment enables the Department to vastly increase the number of students that can safely experience orthopaedic operating theatre procedures in real-time from the surgeon’s point of view, while optimising the quality of the students’ learning.
  • View the full release here: https://www.businesswire.com/news/home/20231011644920/en/
    Nick Cooke, consultant in trauma and orthopaedics at North Tees and Hartlepool NHS Foundation Trust, wears a RealWear healthcare wearable solution to accommodate a diverse group of students, including those training to be paramedics, radiographers and physiotherapists.
  • (Photo: Business Wire)
    The Trust is an integrated hospital and community healthcare organisation serving around 400,000 people in Hartlepool, Stockton-on-Tees and parts of County Durham.
  • “Simplicity, user friendliness and the ability to provide a bird’s-eye view of surgical procedures are the three aspects that are most important to North Tees and Hartlepool NHS Foundation Trust since its deployment,” said Dr. Chris Parkinson, cofounder and CEO at RealWear.

FRANK WARREN JOINS BOXWISE BOARD

Retrieved on: 
Thursday, October 5, 2023
England, Health, Sport, Hope, NMF, Nick Maughan Foundation, United Kingdom, Boxing, Education, Environment, England Boxing, Tourism

LONDON, Oct. 5, 2023 /PRNewswire/ -- BoxWise is delighted to welcome the leading boxing promoter Frank Warren to its advisory board.

Key Points: 
  • LONDON, Oct. 5, 2023 /PRNewswire/ -- BoxWise is delighted to welcome the leading boxing promoter Frank Warren to its advisory board.
  • Since inception BoxWise has attracted the support of various distinguished public figures and is now pleased to have Frank Warren on board.
  • Emphasising the unparalleled ability of boxing to empower young people, Frank commented: 'BoxWise is the most significant boxing charity of our generation, and I am honoured to join the advisory board.
  • BoxWise Founder, Nick Maughan said: 'I am thrilled to have Frank join the team.

Atento Achieves Key Milestone in its Restructuring, Receiving Backstop Commitments for 100% of its Exit Financing

Retrieved on: 
Tuesday, October 3, 2023
CRM, Growth, High court, Youth justice in England and Wales, England, Security (finance), Atento

Atento receives backstop commitments for an additional $76 million in exit financing.

Key Points: 
  • Atento receives backstop commitments for an additional $76 million in exit financing.
  • The exit financing, combined with the extinguishment of $663 million of liabilities pursuant to the Company's restructuring, will provide Atento with additional liquidity for future investment in the business.
  • The Company has successfully secured backstop commitments for 100% of the $76 million in exit financing required to execute its strategic turnaround conditional on the successful implementation of Atento's Restructuring Plan.
  • Atento embarked on this comprehensive restructuring plan with a clear vision to enhance its competitive edge, streamline operations and foster sustainable growth.

Discrimination is the biggest career obstacle for women of colour in the NHS – new research

Retrieved on: 
Tuesday, October 3, 2023
Blood pressure, Workforce, Leadership, NHS Blood and Transplant, Fawcett Society, Blood, Saint Andrew's Society, Workplace, Runnymede, Woman, Research, Transplant, England, Interface (computing), Literature, Runnymede Trust, Patient, Population, Racism, NHS England, NHS, Smoking, Nursing, Management

That same month, Michelle Cox, a healthcare manager and senior nurse, won a case against NHS England and NHS Improvement Commissioning in Manchester.

Key Points: 
  • That same month, Michelle Cox, a healthcare manager and senior nurse, won a case against NHS England and NHS Improvement Commissioning in Manchester.
  • According to NHS data from 2021, black and minority ethnic women are the most likely of all NHS staff groups to experience discrimination from patients or colleagues.
  • My doctoral research looks at the obstacles black and minority ethnic women face in the NHS in terms of career development.

The barriers to career progression

    • I identified eight barriers or drivers (often two sides of the same coin) to career progression for this group.
    • These are: systemic discrimination; leadership and organisational cultures; recruitment and talent management; policies; training; monitoring and accountability; work-life balance; and support.
    • In 2016, minority ethnic NHS staff were 1.56 times more likely to enter formal disciplinary processes than white staff.
    • And they are three times more likely than their peers to think regularly about leaving their jobs.

How discrimination is compounded

    • In the UK, this compounded discrimination is further exacerbated by, among other things, being a migrant or having a non-standard British accent.
    • Accent discrimination can lead to employees receiving poorer pay, having limited access to professional networks, or fewer chances of promotion.
    • Here too, it can see people more likely to leave their jobs.
    • This often has a negative impact on an employee’s mental wellbeing and physical health too.

One Heritage Group plc: Lincoln House Sales Update

Retrieved on: 
Friday, September 29, 2023
Lincoln House, LSE, Heritage, England, Sale

One Heritage Group PLC (LSE: OHG), the UK-based residential developer, development manager and property manager focused on the North of England, on 24 August 2023 announced that it was experiencing delays with the completion of the sale of fifteen units at Lincoln House, Bolton.

Key Points: 
  • One Heritage Group PLC (LSE: OHG), the UK-based residential developer, development manager and property manager focused on the North of England, on 24 August 2023 announced that it was experiencing delays with the completion of the sale of fifteen units at Lincoln House, Bolton.
  • The Company is pleased to confirm that the completion of the remaining fifteen units has now taken place ahead of the updated deadline of 09 October 2023.
  • The funds have been received in full, including an interest payment that the buyer had to pay.
  • The Company looks forward to updating all shareholders on the Full Year Results in Q4 2023.